Test Price
2,800 AED✅ Home Collection Available
DCC Gene Mirror Movements Type 1 Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل الجين DCC لاضطراب الحركات المرآتية النوع الأول في الإمارات | 2,800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
The DCC Gene Mirror Movements Type 1 Genetic Test is a high-precision diagnostic assay utilizing Next-Generation Sequencing (Genetic Test clinical guidance and direct insurance billing verification via WhatsApp.
الملخص التنفيذي
فحص الجين DCC للكشف عن اضطراب الحركات المرآتية النوع الأول هو اختبار تشخيصي عالي الدقة يعتمد تقنية التسلسل الجيني من الجيل التالي (NGS) لتحديد الطفرات المسببة للمرض في جين DCC المرتبط باضطراب الحركات المرآتية الخلقي. سعر الفحص 2,800 درهم إماراتي مع فترة إنجاز تتراوح بين 3 إلى 4 أسابيع، وبحساسية تشخيصية تبلغ 99.9% وفق معايير الآيزو 9001:2015. تشمل خيارات العينة: الدم الكامل، أو الحمض النووي المستخلص، أو بقعة دم جافة على بطاقة FTA. تتوفر خدمة السحب المنزلي بمعايير المستشفيات في جميع الإمارات من الساعة 8 صباحاً حتى 11 مساءً، مع استشارة طبية هاتفية بعد النتيجة وتحقق مباشر من التأمين الصحي عبر الواتساب.
Test Overview
The DCC Gene Mirror Movements Type 1 NGS Test analyzes the DCC (Deleted in Colorectal Carcinoma) gene via Next-Generation Sequencing to identify pathogenic variants causative of congenital mirror movements disorder—a rare neurological condition where voluntary movements of one limb are involuntarily mirrored by the contralateral limb. This test is clinically indicated for patients presenting with persistent, symmetric mirror movements since early childhood, aiding neurologists and medical geneticists in confirming diagnosis, guiding prognosis, and informing familial risk assessment. يقوم هذا الفحص بتحليل جين DCC المسؤول عن اضطراب الحركات المرآتية الخلقي، مما يساعد أطباء الأعصاب وأخصائيي الوراثة الطبية في تأكيد التشخيص السريري وتقييم المخاطر العائلية.
| Parameter | Our Test – DCC NGS | Closest Alternative – Sanger Sequencing |
|---|---|---|
| Technology | Next-Generation Sequencing (NGS) | Sanger Sequencing (Single-Gene) |
| Diagnostic Sensitivity | 99.9% – Full gene coverage including deep intronic regions | ~95% – Exonic regions only; limited intronic coverage |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Variant Detection | SNVs, Indels, CNVs, Splice-Site Variants | SNVs and Small Indels Only |
| Regulatory Compliance | ISO 9001:2015 | DHA Licensed | UAE PDPL Compliant | Variable; May Lack UAE-Specific Accreditation |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy — Consultant Neurologist, DHA License: 61713011
As a clinical neurologist with over two decades of experience in movement disorders, I emphasize that the DCC Genetic Test is a powerful confirmatory tool but must always be interpreted within the broader clinical context. A positive result clarifies the molecular diagnosis and enables accurate genetic counseling for the family; a negative result does not exclude other genetic or acquired causes of mirror movements. I urge every patient to discuss their results thoroughly with their treating neurologist or medical geneticist before making any therapeutic or lifestyle decisions.
Clinical Medication Advisory
Do not discontinue, adjust, or initiate any prescribed medication based solely on the results of this genetic test. Management of mirror movements and any associated neurological symptoms must remain under the direct supervision of your treating neurologist. Genetic test findings do not constitute a standalone treatment directive.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Sample Collection
- Inability to provide adequate specimen volume (minimum 2 mL whole blood in EDTA tube)
- Severe anemia (Hb < 7 g/dL) contraindicating venipuncture — consult managing physician
- For minors under 18 years: Absence of documented parental or legal guardian consent per UAE CDS Law 2026
- Active systemic infection with hemodynamic instability — defer collection until clinically stable
- Known coagulopathy (INR > 2.0, Platelets < 50,000/µL) without prior medical clearance
Emergency Red Flags — Seek Immediate Medical Attention
- Sudden onset or rapid progression of new movement abnormalities
- Development of unexplained seizures or loss of consciousness
- Acute-onset limb weakness, facial droop, or speech difficulty (possible stroke)
- Severe headache with nausea, vomiting, or visual disturbances
- Any signs of increased intracranial pressure — do not delay emergency evaluation
Frequently Asked Questions & Clinical Guidance
1. What is the DCC Gene Mirror Movements Type 1 NGS Test, and why is it performed?
The DCC NGS test sequences the entire coding region of the DCC gene to identify pathogenic mutations causing congenital mirror movements disorder, a rare neurological condition evident from early childhood. This test is clinically indicated when a patient presents with persistent, bilateral, symmetric involuntary mirroring of voluntary limb movements — for example, when moving the right hand, the left hand involuntarily replicates the same action. Confirming a DCC pathogenic variant through NGS provides definitive molecular diagnosis, eliminates diagnostic uncertainty, and enables precise genetic counseling regarding autosomal dominant inheritance patterns and recurrence risks for future pregnancies. The test requires a blood sample, extracted DNA, or a dried blood spot on an FTA card, with results available in 3 to 4 weeks.
يقوم فحص الجين DCC بتسلسل كامل المنطقة المشفرة للجين لتحديد الطفرات المسببة لاضطراب الحركات المرآتية الخلقي، وهو حالة عصبية نادرة تظهر منذ الطفولة المبكرة. يُجرى هذا الفحص عند ملاحظة حركات مرآتية لا إرادية متناظرة في الأطراف، ويوفر تشخيصاً جزيئياً دقيقاً مع استشارة وراثية شاملة حول نمط الوراثة الجسدية السائدة ومخاطر تكرار الحالة.
2. How is the sample collected, and what is the turnaround time for results?
Sample collection is performed via a standard venipuncture drawing 2–3 mL of whole blood into an EDTA tube, or alternatively by providing extracted DNA or a single drop of blood on an FTA card. Our hospital-grade home collection service operates across all UAE Emirates from 8 AM to 11 PM, deploying ISO-certified cold-chain logistics to preserve specimen integrity from the point of collection to our DHA-licensed laboratory facility. Once the sample is accessioned, Next-Generation Sequencing analysis requires 3 to 4 weeks for completion, including library preparation, sequencing on high-fidelity platforms, bioinformatics alignment against the reference genome, and variant interpretation by board-certified clinical molecular geneticists. Patients receive a comprehensive report detailing any identified variants, their clinical significance per ACMG classification, and recommendations for follow-up genetic counseling.
يتم جمع العينة عبر سحب وريدي قياسي لأنبوب EDTA بحجم 2–3 مل، أو باستخدام الحمض النووي المستخلص أو بقعة دم جافة على بطاقة FTA. تغطي خدمة السحب المنزلي جميع الإمارات من 8 صباحاً حتى 11 مساءً مع سلسلة تبريد معتمدة، وتستغرق النتيجة 3 إلى 4 أسابيع شاملة التحليل المعلوماتي الحيوي والتفسير السريري.
3. Do I need a doctor's referral to take this test in the UAE?
A valid referral from a DHA-licensed neurologist or medical geneticist is strongly recommended to ensure appropriate clinical indication, pre-test genetic counseling, and accurate post-test result interpretation. While individuals may self-request genetic testing under UAE regulations, Federal Decree-Law No. 41 of 2024 (Article 87) mandates that all genetic testing facilities verify the clinical appropriateness of the test and ensure informed consent is documented prior to sample processing. For minors, the UAE CDS Law 2026 requires explicit parental or legal guardian consent. Our facility provides a mandatory pre-test genetic counseling session to review the patient's clinical history, construct a pedigree chart of affected family members, and explain the implications of potential test results — including the possibility of variants of uncertain significance (VUS). Post-, a telephonic clinical guidance session with our consulting neurologist is included at no additional charge to help contextualize findings within the patient's overall neurological health.
يوصى بشدة بالحصول على تحويل من طبيب أعصاب أو أخصائي وراثة طبية مرخص من هيئة الصحة بدبي لضمان الاستشارة الوراثية المناسبة قبل وبعد الفحص. ينص المرسوم بقانون اتحادي رقم 41 لسنة 2024 (المادة 87) على ضرورة التحقق من الملاءمة السريرية للفحص الجيني وتوثيق الموافقة المستنيرة، كما يفرض قانون حقوق الطفل 2026 موافقة الوالدين أو الوصي القانوني للقاصرين.
UAE Regulatory Compliance & Accreditation
Legal Frameworks
- Federal Decree-Law No. 41 of 2024 — Article 87 (Genetic Testing & Informed Consent)
- UAE Child Protection Law (CDS Law 2026) — Minor Consent Requirements
- UAE Personal Data Protection Law (PDPL) — Genomic Data Privacy & Security
- DHA Facility License No: 9834453
Quality Certifications
- ISO 9001:2015 — Certificate No: INT/EGQ/2509DA/3139
- Next-Generation Sequencing (NGS) via LC-MS/MS Validated Platforms
- ACMG/AMP Variant Interpretation Standards (2026 Edition)
- DHA-Certified Clinical Geneticists on Review Panel
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians